The European Patent Office published patent application EP3920963A1 for Alexion Pharmaceuticals on March 25, 2026, covering methods for treating intracranial hemorrhage and assessing treatment efficacy. The application includes multiple IPC classifications spanning pharmaceutical compositions (A61K 38/48, A61K 31/444), coagulation-related proteins (C12N 9/64), and diagnostic methods (G01N 33/86), with designated states covering all major European jurisdictions.

This is a patent publication notice with no compliance requirements. Competitors developing treatments for intracranial hemorrhage should review this publication for potential freedom-to-operate implications and consider it in their patent landscape analysis. No immediate action is required, but R&D teams should assess whether this publication affects ongoing development programs.